Your session is about to expire
← Back to Search
Alcohol: Intravenous administration for Bariatric Surgery Candidates (SWAP Trial)
SWAP Trial Summary
This trial will study the effects of alcohol on people who are scheduled for Roux-en-Y gastric bypass surgery, with follow-ups 3 and 9 months after surgery.
SWAP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SWAP Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there current opportunities to volunteer for this research project?
"This research programme, which was initiated on February 10th 2020 and most recently modified on May 19th 2022, is actively seeking enrolment. Clinicaltrials.gov provides the latest updates related to this study's recruitment status."
Could I be considered as a potential participant in this experiment?
"This medical experiment is seeking 20 participants between the ages of 30 and 55 who have undergone bariatric surgery. The most important requirements are that applicants fit the following criteria; female, non-smoker, BMI greater than 35kg/m2 with body weight less than 450 lbs., moderate alcohol consumption as per NIH/NIAAA standards (3 - 7 standard drinks a week for women), and fall within either upper or lower tercile on ASQ scores based on investigator's studies."
Are participants who are under 45 years of age accepted into this investigation?
"This medical study is seeking out individuals between the ages of 30 and 55 years old."
What is the breadth of participant enrolment for this clinical investigation?
"Affirmative, the listing on clinicaltrials.gov reveals that this investigation is currently registering participants. Initially posted in February of 2020, it was most recently edited in May 2022 and seeks to enroll 20 people across a single site."
What medical disorder is Alcohol: Intravenous administration most typically utilized to address?
"Alcohol: Intravenous administration is a viable treatment for obstructive hypertrophic cardiomyopathy, communicable diseases, and ethylene glycol."
Share this study with friends
Copy Link
Messenger